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You may remember a dog named Lancelot. In 2001, Dr. Gustavo D. Aguirre, professor of medical genetics and ophthalmology at Penn Vet, restored vision to the dog, who was born blind – 
and they both made national headlines.
Their next stop? Washington, DC. 
“Because of publicity following Lancelot’s recovery of 
vision, he was invited to Capitol Hill to meet with members 
of Congress,” said Dr. Aguirre. “During the meeting, 
Lancelot laid down near the podium and looked carefully at 
all the members of the audience who asked questions. Unlike 
dogs that are blind but can hear, Lancelot fixed his stare on 
the people who asked questions.”
Dr. Aguirre’s goal in traveling to Washington with 
Lancelot was to get people to understand and appreciate 
the power of and need to continue to develop new therapy 
technologies for treating inherited blindness.
Their sojourn to Washington was a success and Dr. 
Aguirre’s point was made. 
“They all wanted to adopt Lancelot,” said Dr. Aguirre, “so 
to me that meant they connected with the idea that this kind 
of work is important.”
Serving as lead researcher of the project at the time, Dr. 
Aguirre’s work began with Lancelot and a team that included 
researchers at Penn’s Scheie Eye Institute and University of 
Florida. Their goal was to restore vision to Lancelot and his 
littermates that were mixed-breed dogs of Briard origin. This 
is the first time that gene therapy was used to successfully 
restore vision to any living creature. 
By injecting a genetically engineered virus carrying a 
healthy copy of the defective gene into the part of the dog’s 
retina that contained the retinal pigment epithelium, the cell 
layer that is essential for the proper 
functioning of the light-sensing 
cells, Dr. Aguirre and his team 
were able to “infect” those cells 
with normal gene material. Within 
several weeks, cells with the 
healthy copy of the gene began to 
produce vitamin A in the proper 
form needed by the retina that, in 
combination with opsin, formed 
the visual pigment rhodopsin, 
allowing Lancelot to see. 
This advance in veterinary medicine offers hope for curing 
a similar disease that blinds children at birth or in early child-
hood – Leber’s congenital amaurosis (LCA), an inherited retinal 
disease. And, because of the dog’s successful treatment, human 
clinical trials began in 2007 at several centers worldwide, 
including the University College of London, the Sheie Eye 
Institute and Children’s Hospital of Philadelphia. 
But Dr. Aguirre’s and his colleagues’ passion for restoring 
sight to the blind using gene therapy didn’t stop with Lancelot.
A SECOND MAJOR BREAKTHROUGH
Working hand-in-hand with researchers at Temple 
University, University of Florida and Cornell University,  
Dr. András M. Komáromy, assistant professor of 
ophthalmology – one of Dr. Aguirre’s colleagues – has 
made another major breakthrough in vision recovery with 
developing a gene therapy to treat achromatopsia in dogs. 
Otherwise known as day blindness, rod monochromacy or 
total color blindness, achromatopsia affects the cones in the 
eye and makes daytime vision impossible for affected dogs. 
Penn Vet ophthalmologists’ work in the lab restores 
vision to dogs and provides hope to human patients
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Day blindness is rare in humans, affecting approximately one 
out of every 30,000 to 50,000, but because it affects the cones 
in the eye, Dr. Komáromy, lead author on the study, says it’s 
a perfect model to study other diseases affecting the cones, like 
macular degeneration in humans. Cones, responsible for day and 
color vision, are essential for central visual acuity and most daily 
visual activities. 
The gene therapy developed by Dr. Komáromy is delivered 
directly to the cone cells in the retina and targets mutations of the 
CNGB3 gene – a mutation discovered by Dr. Aguirre’s research 
group several years ago. The CNGB3 gene codes for an ion 
channel that is crucial for normal cone function.
“We administer the virus carrying a normal copy of the 
CNGB3 gene underneath the retina,” said Dr. Komáromy. “The 
treated part of the retina is temporarily detached following the 
injection. The eye is an enclosed organ so you can inject high 
doses exactly where you need it.”
“It’s the same gene responsible for 50 – 80 percent of human 
achromatopsia,” said Dr. Aguirre. “This work can help researchers 
understand how to fight age-related macular degeneration in 
people, which is the leading cause of blindness in people over 60.”
“Dogs don’t have a well developed macula as in humans,” said 
Dr. Komáromy, “but because achromatopsia is a model cone 
disease, it allows us to answer questions for human medicine and 
consider important factors like age and allows us to follow up over 
a long period of time.” 
Dr. Komáromy’s treatment cured younger canines regardless 
of the mutation that caused their achromatopsia and was effective 
for the 33-month span of the study. The successful restoration 
of cone function was documented through a technique called 
electroretinography. Researchers also measured the dogs’ ability to 
negotiate a short obstacle course in daylight. 
“I remember the moment very well during the summer of 2006 
when I recorded the recovered cone function for the first time 
by electroretinography,” said Dr. Komáromy. “I became very 
excited, but I repeated the recordings multiple times and kept 
replacing the electrode wires to make sure that I was not dealing 
with a technical artifact...the cone signal persisted!”
While younger dogs had tremendous success with this kind of 
gene therapy, dogs older than 54 weeks of age had less success. 
“Because of the success in younger dogs, it makes sense to keep 
going,” said Dr. Komáromy. “We want to develop a treatment for 
older dogs.”
The results represent the second successful cone-directed gene 
replacement therapy in achromatopsia animal models and the first 
outside of mouse models. 
The work done by Drs. Komáromy and Aguirre holds promise 
for future human clinical trials of cone-directed gene therapy in 
achromatopsia and other cone-specific disorders. It holds great 
promise to treat dog-specific diseases like the Progressive Rod-
Cone Degeneration (PRCD), a hereditary retinal disease that leads 
to blindness in dogs between the ages of three to seven years, and 
is the most common cause of inherited canine blindness. 
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More Work in the Lab
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